Abivax stock has far outperformed the broader index with a stellar performance, even as the company is making big financial losses.
Get this delivered to your inbox, and more info about our products and services.
Europe's best performing stock in 2025, Abivax, could be snapped up any day now, analysts say.
The investment bank upgraded the pharma stock to overweight from equal weight.
The bank initiated the clinical-stage biotechnology firm at a buy rating.
As of Wednesday's nearly record-high close of around $350, the stock was already up nearly 12% year to date.
We're taking off more of this stock as shares hit a new record high Wednesday.
The bank believes gave a boost to the company following its earnings report that delivered strong guidance for 2026.
